Since establishing its Vietnam subsidiary in 2024, Celltrion has launched two major biosimilars: Remsima (infliximab) in June and Herzuma (trastuzumab) in August. The company secured a one-year supply contract with Vietnam’s largest military hospital and won a two-year tender to supply Herzuma to medical institutions in the south-central region. Celltrion is also gearing up to introduce Remsima SC (a subcutaneous formulation of infliximab) and Truxima (rituximab) in the second half of the year, accelerating its portfolio expansion.
Vietnam’s pharmaceutical market, valued at approximately $8.5 billion in 2023, has grown at an average annual rate of over 7% in the past decade. Celltrion’s key biologics account for roughly $145 million in the public-sector market, with an annual growth rate exceeding 10%.
The company is leveraging a tailored direct-sales strategy to strengthen its competitive edge in hospital tenders, while fostering close collaboration with local healthcare professionals and regulatory authorities. This includes sharing expertise from South Korea’s advanced medical ecosystem to enhance Vietnam’s healthcare infrastructure.
“Vietnam’s rapidly growing market presents a significant opportunity to expand access to high-quality biologics,” said Seung-seob Jung, Celltrion’s head of Central Asia operations. “By strengthening our direct-sales capabilities and deepening Korea-Vietnam pharmaceutical and biotech collaboration, we aim to further scale our presence.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
